Literature DB >> 18536653

Clear cell carcinoma of the pancreas: histopathologic features and a unique biomarker: hepatocyte nuclear factor-1beta.

Lisa Kim1, Jie Liao, Meng Zhang, Mark Talamonti, David Bentrem, Sambasiva Rao, Guang-Yu Yang.   

Abstract

Clear cell carcinoma as a variant of ductal carcinoma of the pancreas is not well recognized. Hepatocyte nuclear factor-1beta as a transcription factor has been identified as a specific biomarker of clear cell tumor of the female genital tract. The aim of this study was to systematically analyze clear cell carcinoma of the pancreas and its unique biomarker hepatocyte nuclear factor-1beta. A total of 84 pancreatic adenocarcinomas were analyzed pathologically and with an immunohistochemical approach with hepatocyte nuclear factor-1beta antibody. The identified clear cell carcinomas were further studied by PAS, DPAS, and mucicarmine stains. Pathologic features and clinical follow-up were documented. Of them, 20 (24%) pancreatic adenocarcinomas were identified with clear cell features, including 12 clear cell carcinomas and 8 ductal adenocarcinomas with clear cell component (defined as less than 75% of tumor with clear cells). Cytologically, the clear cell carcinomas exhibited clear cytoplasm with centrally located, atypical nuclei. PAS, DPAS, and mucicarmine stains confirmed that the clear cytoplasm was not due to accumulation of glycogen or mucin. The results of immunostaining showed that hepatocyte nuclear factor-1beta is overexpressed in all clear cell carcinomas and in the clear cell components of eight ductal carcinomas with clear cell features. In contrast, in usual ductal adenocarcinoma, hepatocyte nuclear factor-1beta exhibited overall weak or focally moderate staining; only eight cases were strongly positive (15%) of which 38% were high grade and 63% were moderate grade. However, when included with the strong staining cases in mixed and clear cell carcinoma, this group regardless of morphology appeared to correlate with worse survival compared to the group with weak hepatocyte nuclear factor-1beta staining across morphologies (P<0.01). Thus, clear cell carcinoma of the pancreas is not an uncommon variant of pancreatic ductal adenocarcinoma. Hepatocyte nuclear factor-1beta is a useful marker to identify these clear cell carcinomas, and its overexpression may aid in stratifying survival rate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18536653     DOI: 10.1038/modpathol.2008.95

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  24 in total

1.  A 71-year-old man with a large cystic pancreatic mass.

Authors:  Deborah Mukherji; Walid Faraj; Mohamed Khalife; Ali Shamseddine; Nadim El Majzoub; Ghazi Zaatari; Manish Shah; Ghassan K Abou-Alfa; Eileen M O'Reilly
Journal:  Gastrointest Cancer Res       Date:  2012-01

Review 2.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

3.  HNF-1β in ovarian carcinomas with serous and clear cell change.

Authors:  Deborah DeLair; Guangming Han; Julie A Irving; Samuel Leung; Carol A Ewanowich; Teri A Longacre; Cyril B Gilks; Robert A Soslow
Journal:  Int J Gynecol Pathol       Date:  2013-11       Impact factor: 2.762

4.  Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions.

Authors:  Kristýna Němejcová; Ivana Tichá; Petra Kleiblová; Michaela Bártů; David Cibula; Kateřina Jirsová; Pavel Dundr
Journal:  Pathol Oncol Res       Date:  2015-12-19       Impact factor: 3.201

5.  Utility of HNF-1B and a panel of lineage-specific biomarkers to optimize the diagnosis of pancreatic ductal adenocarcinoma.

Authors:  Shi Bai; James Lindberg; Giles Whalen; Venu Bathini; Jian Zou; Michelle X Yang
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

6.  Absence of HIF1A Leads to Glycogen Accumulation and an Inflammatory Response That Enables Pancreatic Tumor Growth.

Authors:  Marco Maruggi; Fabiana Izidro Layng; Robert Lemos; Guillermina Garcia; Brian P James; Monica Sevilla; Ferran Soldevilla; Bas J Baaten; Petrus R de Jong; Mei Yee Koh; Garth Powis
Journal:  Cancer Res       Date:  2019-10-04       Impact factor: 12.701

7.  Clear cell carcinoma of the pancreas--a case report and review of the literature.

Authors:  Hui-Young Lee; Dong-Gyu Lee; Kwangjin Chun; Seungkoo Lee; Seo-Young Song
Journal:  Cancer Res Treat       Date:  2009-09-29       Impact factor: 4.679

8.  Clear cell adenocarcinoma presenting as acute pancreatitis: A rare form of primary pancreatic malignancy.

Authors:  Robert S O'Neill; Lyn L Lam; Parthsinh Solanki; Robyn Levingston; David Thomas
Journal:  Cancer Rep (Hoboken)       Date:  2020-08-09

9.  Genome-wide association study identifies a common variant associated with risk of endometrial cancer.

Authors:  Amanda B Spurdle; Deborah J Thompson; Shahana Ahmed; Kaltin Ferguson; Catherine S Healey; Tracy O'Mara; Logan C Walker; Stephen B Montgomery; Emmanouil T Dermitzakis; Paul Fahey; Grant W Montgomery; Penelope M Webb; Peter A Fasching; Matthias W Beckmann; Arif B Ekici; Alexander Hein; Diether Lambrechts; Lieve Coenegrachts; Ignace Vergote; Frederic Amant; Helga B Salvesen; Jone Trovik; Tormund S Njolstad; Harald Helland; Rodney J Scott; Katie Ashton; Tony Proietto; Geoffrey Otton; Ian Tomlinson; Maggie Gorman; Kimberley Howarth; Shirley Hodgson; Montserrat Garcia-Closas; Nicolas Wentzensen; Hannah Yang; Stephen Chanock; Per Hall; Kamila Czene; Jianjun Liu; Jingmei Li; Xiao-Ou Shu; Wei Zheng; Jirong Long; Yong-Bing Xiang; Mitul Shah; Jonathan Morrison; Kyriaki Michailidou; Paul D Pharoah; Alison M Dunning; Douglas F Easton
Journal:  Nat Genet       Date:  2011-04-17       Impact factor: 38.330

Review 10.  The biology of pancreatic cancer morphology.

Authors:  Oliver G McDonald
Journal:  Pathology       Date:  2021-12-03       Impact factor: 5.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.